Biomarker-Driven Lung Cancer | Clinical

RET, MET Inhibitors Advance Targeted Therapies in NSCLC

December 28, 2020

FDA approvals of novel agents for molecularly defined subtypes of non–small cell lung cancer are poised to change both patient outcomes as well as pretreatment testing requirements for those harboring these tumors.

FDA Approval Sought for Sotorasib in Patients With KRAS G12C+ Locally Advanced or Metastatic NSCLC

December 17, 2020

A New Drug Application was submitted to the FDA seeking approval of the investigational KRAS G12C inhibitor sotorasib as treatment of patients with KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer, as determined by an FDA-approved test, following at least 1 prior systemic therapy.

FDA Grants Sotorasib Breakthrough Therapy Designation for Advanced KRAS G12C-Mutant NSCLC

December 08, 2020

The FDA granted a Breakthrough Therapy designation to sotorasib for the treatment of patients with locally advanced or metastatic non–small cell lung cancer who harbored a KRAS G12C mutation following at least 1 prior line of systemic therapy.

Spira Recognizes Advances in Biomarker-Driven Disease During Lung Cancer Awareness Month

November 17, 2020

In an interview with Targeted Oncology, Alexander Spira, MD, PhD, discussed the role of identifying biomarkers in patients with lung cancer based on the vast amount of data and significant number of approved therapies available for biomarker-driven disease.